Drug Detail:Synagis (Palivizumab [ pal-i-viz-oo-mab ])
Generic Name: PALIVIZUMAB 100mg in 1mL
Dosage Form: injection, solution
Drug Class: Immune globulins
Drug Detail:Synagis (Palivizumab [ pal-i-viz-oo-mab ])
Generic Name: PALIVIZUMAB 100mg in 1mL
Dosage Form: injection, solution
Drug Class: Immune globulins
The recommended dose of Synagis is 15 mg per kg of body weight given monthly by intramuscular injection. The first dose of Synagis should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season. In the northern hemisphere, the RSV season typically commences in November and lasts through April, but it may begin earlier or persist later in certain communities.
Synagis serum levels are decreased after cardio-pulmonary bypass [see Clinical Pharmacology (12.3)]. Children undergoing cardio-pulmonary bypass should receive an additional dose of Synagis as soon as possible after the cardio-pulmonary bypass procedure (even if sooner than a month from the previous dose). Thereafter, doses should be administered monthly as scheduled.
The efficacy of Synagis at doses less than 15 mg per kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.